You searched for "diagnostics"
Demanding cases or nightmares in uro-oncology? May/Jun 2022
Delayed diagnosis of testicular cancer Testicular cancer is considered rare in the general population but is the most common cancer affecting males between 24 and 49 years. The diagnosis of testicular cancer depends on physical examination, ultrasound findings and tumour...Renal oncocytoma: Diagnosis and surveillance strategy
Renal oncocytoma is one of the most common benign renal neoplasms, accounting for around 3–7% of all renal tumours, and up to 18% of all small renal masses (SRMs) measuring less than 4cm [1, 2]. Most oncocytomas are asymptomatic and...
The case against omitting systematic biopsy in younger men
In this issue of European Urology, Al-Monajjed et al. report findings from the PROBASE trial, which evaluated prostate cancer (PC) detection in men aged 45–50 years with PSA ≥3ng/ml using both MRI-targeted biopsy (TBx) and systematic biopsy (SBx). Among 525...The Future of Prostate Cancer Imaging: What’s Next?
The pioneering charity Prostate Cancer Research convened industry leaders, NHS experts and patients for a webinar exploring how artificial intelligence (AI) is transforming prostate cancer imaging and clinical pathways. The session provided valuable insights for healthcare professionals seeking innovative approaches...Bupa covers accurate PSE prostate cancer blood test
A new era in prostate cancer detection is emerging with the EpiSwitch® PSE blood test, a highly accurate tool that enhances early diagnosis while significantly cutting false positives. Now covered by Bupa as a pre-biopsy test, PSE has demonstrated 94%...
Refining management of non-visible haematuria
The optimal evaluation of non-visible haematuria (NVH) continues to be debated, with competing interests of avoidance underdiagnosis and the harms of over-testing. Current National Institute for Health & Care Excellent (NICE) guidance recommends referral for patients ≥60 years with NVH....Using change theories can help nurses implement better care in prostate cancer
Nurses can help support change in prostate cancer care by understanding change management and models and provide leadership in improving prostate cancer care. An important part of being able to lead change is to understand change theories such as the...
Are standard repeat biopsies during active surveillance for prostate cancer still necessary?
Active surveillance (AS) has emerged as a key strategy for managing low-risk prostate cancer (PCa), offering an alternative to immediate treatment. Initially, AS relied on prostate specific antigen (PSA) testing, digital rectal examinations (DRE), and systematic biopsies. Early studies using...Józef Dietl – more than one crisis
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). To urologists, the name Dietl is linked with the eponym of Dietl’s crisis,...The importance of active investigation and follow-up in bladder injury
Bladder injury (BI) is uncommon, and patients are typically managed by large multidisciplinary teams, dealing concomitantly with other injuries or diagnoses. BI can be categorised by cause (traumatic vs. iatrogenic) or anatomical location (intraperitoneal vs. extraperitoneal), requiring differing approaches to...New study shows UK may finally be ready for prostate cancer screening
Prostate Cancer UK study shows tens of thousands fewer men each year face unnecessary harm thanks to new screening techniques. New research by Prostate Cancer UK shows that the UK may finally be in a position to roll out a...
